Filing Flows › Comparisons › KURA vs TBPH
Kura Oncology vs Theravance Biopharma: KURA and TBPH compared
Kura Oncology is the larger company: $20.9M of revenue in its latest quarter (Q2 2026) against $20.7M for Theravance Biopharma (Q2 2026). Kura Oncology is growing faster (+36% against -21% a year earlier). Theravance Biopharma is more profitable, with an operating margin of -39.9% against -349.8%.
Where the money goes: KURA and TBPH
Kura Oncology (KURA) · Q2 2026
Kura Oncology, Q2 2026: revenue $20.9M (+36% year over year), operating margin -349.8%, net loss $68.3M, operating cash flow −$62.5M. The chart follows the revenue to costs, profit and cash.
Theravance Biopharma (TBPH) · Q2 2026
Theravance Biopharma, Q2 2026: revenue $20.7M (-21% year over year), operating margin -39.9%, net loss $5.9M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
| Kura Oncology (KURA) | Theravance Biopharma (TBPH) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $20.9M | $20.7M |
| Revenue growth, Y/Y | +36% | -21% |
| Operating margin | -349.8% | -39.9% |
| Net earnings | −$68.3M | −$5.9M |
| Net margin | -327.3% | -28.5% |
| Operating cash flow | −$62.5M | −$7.0M |
Where the revenue comes from
Kura Oncology
- License and Collaboration Revenue: $11.8M (56%)
- Product: $9.1M (44%)
Questions
Which is bigger, Kura Oncology or Theravance Biopharma?
Kura Oncology is the larger company: $20.9M of revenue in its latest quarter (Q2 2026) against $20.7M for Theravance Biopharma (Q2 2026).
Is Kura Oncology or Theravance Biopharma growing faster?
Kura Oncology is growing faster (+36% against -21% a year earlier).
Which is more profitable, Kura Oncology or Theravance Biopharma?
Theravance Biopharma is more profitable, with an operating margin of -39.9% against -349.8%.
More: Kura Oncology earnings · how Kura Oncology makes money · Theravance Biopharma earnings · how Theravance Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.